Discussion
The first participant has been dosed in a Phase 1/2a clinical trial testing PRO-1562, an experimental oral treatment designed to repair myelin, the protective sheath around nerve fibers that is damaged in people with multiple sclerosis (MS). Developed by Progentos Therapeutics, PRO-1562 aims to…